Medicinova (MNOV) to discontinue development of SARS-CoV-2 vaccine for COVID-19

March 3, 2021 6:33 AM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an update on the development of a SARS-CoV-2 vaccine for COVID-19. MediciNova has conducted a careful review of its numerous development programs to determine the best allocation of resources going forward considering the stage of development, expected costs of completing clinical development, and the competitive landscape. Given the COVID-19 vaccines currently in use and other vaccines in advanced stages of development, MediciNova has decided to discontinue development of a SARS-CoV-2 vaccine for COVID-19 in order to maintain adequate resources for its other development programs which have indications with larger unmet medical needs and market opportunities.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot FDA News

Related Entities